VERACYTE, INC.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| VERACYTE, INC. | |
| By: | /s/ MARC STAPLEY |
| Marc StapleyChief Executive Officer and Director |
Date: February 26, 2026
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENT, that each person whose signature appears below constitutes and appoints Marc Stapley and Rebecca Chambers, and each of them, his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this annual report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons, on behalf of the registrant on the dates and the capacities indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ MARC STAPLEY | Chief Executive Officer and Director(Principal Executive Officer) | February 26, 2026 |
| Marc Stapley | ||
| /s/ REBECCA CHAMBERS | Chief Financial Officer (Principal Financial Officer) | February 26, 2026 |
| Rebecca Chambers | ||
| /s/ JONATHAN WYGANT | Chief Accounting Officer (Principal Accounting Officer) | February 26, 2026 |
| Jonathan Wygant | ||
| /s/ ROBERT S. EPSTEIN, M.D., M.S. | Chairperson and Director | February 26, 2026 |
| Robert S. Epstein, M.D., M.S. | ||
| /s/ ELIAV BARR, M.D. | Director | February 26, 2026 |
| Eliav Barr, M.D. | ||
| /s/ MUNA BHANJI | Director | February 26, 2026 |
| Muna Bhanji | ||
| /s/ KARIN EASTHAM | Director | February 26, 2026 |
| Karin Eastham | ||
| /s/ JENS HOLSTEIN | Director | February 26, 2026 |
| Jens Holstein | ||
| /s/ EVAN JONES | Director | February 26, 2026 |
| Evan Jones | ||
| /s/ TOM MILLER | Director | February 26, 2026 |
| Tom Miller | ||
| /s/ BRENT SHAFER | Director | February 26, 2026 |
| Brent Shafer | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.